02.10.2017 • NewsDede WillamsBluestarAsahi Kasei

Asahi Kasei and Bluestar Studying mPPE

(c) mmmx/Shutterstock
(c) mmmx/Shutterstock

Japan’s Asahi Kasei and China’s Bluestar, a ChemChina subsidiary, have agreed to study the economics of building production facilities for producing a modified polyphenylene ether (mPPE) in China.

The facilities would include the intermediates 2,6-xylenol and polyphenylene ether (PPE). Following completion of detailed feasibility studies, the companies plan to make a final investment decision by March 2018.

The plans will be realized by a joint venture agreed in February of this year and will leverage Bluestar’s technology for 2,6-xylenol and PPE in combination with Asahi Kasei’s mPPE compounding technology and applications development capability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.